Acumen Pharmaceuticals 将来の成長
Future 基準チェック /06
Acumen Pharmaceuticalsの収益は年間6.1%で減少すると予測されていますが、年間収益は年間68.8%で増加すると予測されています。EPS は年間 増加すると予測されています。自己資本利益率は 3 年後に-197.9% 14.7%なると予測されています。
主要情報
-6.1%
収益成長率
14.72%
EPS成長率
| Biotechs 収益成長 | 25.2% |
| 収益成長率 | 68.8% |
| 将来の株主資本利益率 | -197.92% |
| アナリストカバレッジ | Low |
| 最終更新日 | 15 May 2026 |
今後の成長に関する最新情報
Recent updates
新しいナラティブ • May 17
Oligomer Antibody And Brain Delivery Advances Will Reshape Early Alzheimer Treatment Prospects
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing a beta oligomer targeted antibody therapies for Alzheimer’s disease. What are the underlying business or industry changes driving this perspective?分析記事 • Aug 05
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jul 30
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Summary Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ABOS for significant market share if successful. Sabirnetug’s Phase 1 trial showed promising results, reducing brain amyloid plaques and supporting its mechanism of action for treating early Alzheimer's disease. Acumen Pharmaceuticals has a healthy cash runway, estimated at 3.5 years, and appears undervalued relative to its peers in the biotech sector. Despite the promising data, investing in ABOS is speculative due to the early stages of research and the potential long timeline to FDA approval. Read the full article on Seeking Alpha分析記事 • Apr 21
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Sep 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Feb 01
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Oct 16
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 28
Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
The shares of microcap biotech Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) more than doubled in value on Wednesday after its rivals Biogen (BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESALY) announced promising late-stage data for experimental Alzheimer's therapy, lecanemab. In the trial involving nearly 1,800 patients, the amyloid targeting monoclonal antibody cut the cognitive and functional decline in the early stage of Alzheimer's by 27%, compared to placebo, the companies announced late Tuesday. With data validating the amyloid hypothesis in Alzheimer's, developers with similar drugs in their pipeline surged in value. Acumen (ABOS) is advancing its only drug candidate, ACU193 for Alzheimer's, with topline data from a Phase 1 trial expected in H1 2023. ACU193 is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers, which, according to the company, are the most toxic and pathogenic form of amyloid-beta.Seeking Alpha • Jun 30
Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
H.C. Wainwright has initiated Acumen Pharmaceuticals (NASDAQ:ABOS) with a buy rating saying the biopharma's early-stage Alzheimer's candidate, ACU193, has promise. The firm has a $15 price target (~207% return based on Wednesday's closing price). Unlike many other Alzheimer's therapies in development -- and marketed ones such as Biogen's (BIIB) Aduhelm (aducanumab) -- that target the removal of beta amyloid plaque from the brain, ACU193 works differently as a anti-amyloid-beta oligomer (AβO) monoclonal antibody. Analyst Andrew Fein noted that ACU193 "lacks the inflammatory effector functions of other [immunoglobulin] subclasses, thereby making it less prone to [amyloid-related imaging abnormalities], a major safety issue with current anti-[amyloid beta] therapies. Acumen (ABOS) said ACU193 prevents toxic AβOs from binding to dendritic spines and preserves neural function. The company added the candidate has the potential for disease slowing as well as cognitive improvement. The ongoing phase 1 trial is expected to enroll 62 subjects with mild cognitive impairment or mild dementia.分析記事 • May 10
We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Jan 07
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Oct 01
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 4 | -108 | -140 | -193 | 3 |
| 12/31/2027 | N/A | -118 | -124 | -153 | 4 |
| 12/31/2026 | N/A | -84 | -91 | -91 | 5 |
| 3/31/2026 | N/A | -113 | -106 | -106 | N/A |
| 12/31/2025 | N/A | -121 | -116 | -116 | N/A |
| 9/30/2025 | N/A | -133 | -124 | -124 | N/A |
| 6/30/2025 | N/A | -137 | -118 | -118 | N/A |
| 3/31/2025 | N/A | -116 | -103 | -102 | N/A |
| 12/31/2024 | N/A | -102 | -86 | -86 | N/A |
| 9/30/2024 | N/A | -82 | -67 | -67 | N/A |
| 6/30/2024 | N/A | -65 | -56 | -56 | N/A |
| 3/31/2024 | N/A | -56 | -51 | -51 | N/A |
| 12/31/2023 | N/A | -52 | -43 | -43 | N/A |
| 9/30/2023 | N/A | -49 | -46 | -46 | N/A |
| 6/30/2023 | N/A | -46 | -42 | -42 | N/A |
| 3/31/2023 | N/A | -45 | -37 | -37 | N/A |
| 12/31/2022 | N/A | -43 | -35 | -35 | N/A |
| 9/30/2022 | N/A | -38 | -28 | -28 | N/A |
| 6/30/2022 | N/A | -32 | -26 | -26 | N/A |
| 3/31/2022 | N/A | -83 | -24 | -24 | N/A |
| 12/31/2021 | N/A | -101 | -18 | -18 | N/A |
| 9/30/2021 | 0 | -93 | -17 | -17 | N/A |
| 6/30/2021 | 1 | -92 | -11 | -11 | N/A |
| 3/31/2021 | 1 | -32 | -8 | -8 | N/A |
| 12/31/2020 | 1 | -7 | -7 | -7 | N/A |
| 12/31/2019 | 2 | -8 | N/A | -7 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: ABOS今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: ABOS今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: ABOS今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: ABOS来年は収益がないと予測されています。
高い収益成長: ABOS来年は収益がないと予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: ABOS 3 年以内に赤字になると予測されています。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 12:07 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Acumen Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Jason Zemansky | BofA Global Research |
| Thomas Shrader | BTIG |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |